Treace Medical Concepts, Inc. (TMCI) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Treace Medical Concepts Reports Second Quarter 2023 Financial Results
August 8, 2023 4:05 PM EDTPONTE VEDRA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (Treace or the Company) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction Procedure, today reported financial results for the second quarter ended June 30, 2023.
Recent Highlights:
Revenue of $42.0 million in the second quarter of 2023, a 40% increase over same period last yearBlended average revenue per Lapiplasty®... More